Add to Favorites Newsroom RSS Share
Houston, TX USA

Our News on Newswise

100765 Kantarjian_H.jpg

New Approach to Cancer Research Aims to Accelerate Studies and Reduce Cost

A new model for improving how clinical trials are developed and conducted by bringing together academic cancer experts and pharmaceutical companies is being tested by research experts at The University of Texas MD Anderson Cancer Center.
14-May-2018 10:05 AM EDT Add to Favorites


Preclinical MD Anderson Study Suggests ARID1a May Be Useful Biomarker for Immunotherapy

Functional loss of ARID1a, a frequently mutated tumor suppressor gene, causes deficiencies in normal DNA repair and may sensitize tumors to immune checkpoint blockade therapies, according to researchers from The University of Texas MD Anderson...
3-May-2018 2:05 PM EDT Add to Favorites

MD Anderson, Spectrum Pharmaceuticals Complete Poziotinib Licensing Deal

The University of Texas MD Anderson Cancer Center and Spectrum Pharmaceuticals have signed a licensing agreement that covers discoveries by MD Anderson researchers about the company’s drug poziotinib, a targeted therapy for lung cancer.
3-May-2018 12:05 PM EDT Add to Favorites


RNA Editing Study Shows Potential for More Effective Precision Cancer Treatment

If there is one thing all cancers have in common, it is they have nothing in common. A multi-center study led by The University of Texas MD Anderson Cancer Center has shed light on why proteins, the seedlings that serve as the incubator for many...
26-Apr-2018 8:05 AM EDT Add to Favorites


Size, Structure Help Poziotinib Pose Threat to Deadly Exon 20 Lung Cancer

A drug that failed to effectively strike larger targets in lung cancer hits a bulls-eye on the smaller target presented by a previously untreatable form of the disease, researchers at The University of Texas MD Anderson Cancer Center report in...
23-Apr-2018 10:00 AM EDT Add to Favorites


Study May Explain Why Some Triple-Negative Breast Cancers Are Resistant to Chemotherapy

Triple-negative breast cancer (TNBC) is an aggressive form of the disease accounting for 12 to 18 percent of breast cancers. It is a scary diagnosis, and even though chemotherapy can be effective as standard-of-care, many patients become resistant...
19-Apr-2018 9:05 AM EDT Add to Favorites


Combination Therapy Strengthens T Cells in Melanoma Pre-Clinical Study

A pre-clinical study of two drugs designed to boost T cell performance, has revealed the agents, when give in combination, may enhance the immune system’s ability to kill melanoma tumors deficient in the tumor suppressor gene PTEN. The study was...
16-Apr-2018 10:05 AM EDT Add to Favorites


Precancerous Colon Polyps in Patients with Lynch Syndrome Exhibit Immune Activation

Colon polyps from patients with Lynch syndrome, a hereditary condition that raises colorectal cancer risk, display immune system activation well before cancer development, according to research from The University of Texas MD Anderson Cancer Center....
13-Apr-2018 4:25 PM EDT Add to Favorites

see all news

Our Experts on Newswise


Mastectomy Plus Reconstruction Has Highest Rate of Complication, Complication-Related Costs of Guideline-Concordant Therapies for Early Breast Cancer

In a review of guideline-concordant treatment modalities for women with early stage breast cancer, mastectomy and reconstruction had the highest rate of complications and complication-related costs, regardless of age.
27-Sep-2016 3:05 PM EDT


Can Gender Play a Role in Determining Cancer Treatment Choices?

It is well known that men and women differ in terms of cancer susceptibility, survival and mortality, but exactly why this occurs at a molecular level has been poorly understood.
9-May-2016 12:00 PM EDT


MD Anderson Study Reveals New Insight Into Tumor Progression

Scientists know that activation of growth factor receptors like epidermal growth factor receptors (EGFR) promote tumor progression in many types of cancer.
17-Aug-2015 11:00 AM EDT


Poor Survival Among Colorectal Cancer Patients Tied to Biomarker CSN6

A protein called CSN6 has been found to be correlated with poor survival among patients with colorectal cancer, according to a study at The University of Texas MD Anderson Cancer Center.
10-Aug-2015 12:00 PM EDT


MD Anderson Study Predicts New Hepatitis C Drugs Will Place a Dramatic Financial Strain on the Health Care System

The cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous economic burden on the country’s health care system. The prediction comes from a cost-effectiveness analysis led by...
16-Mar-2015 6:00 PM EDT

MD Anderson Joins CATCH Global Foundation to Boost Child Health, Prevent Cancer in Later Years

Cancer prevention experts at The University of Texas MD Anderson Cancer Center have allied with the CATCH Global Foundation, whose comprehensive child health program reaches children and their families in more than 10,000 educational settings...
18-Feb-2015 10:00 AM EST

MD Anderson Energy Balance Expert Available for Obesity, Cancer Stories

30-Oct-2013 8:10 PM EDT

MD Anderson Obesity and Cancer Expert Researches Food Addiction

30-Oct-2013 8:00 PM EDT

see all experts

Our YouTube Videos

Chat now!